Ulipristal acetate: Ph III Venus II data

Top-line from the double-blind, U.S. Phase III Venus II trial in 432 premenopausal women ages 18-50 with abnormal bleeding due to uterine fibroids showed that 5 and 10 mg oral ulipristal acetate each met the co-primary endpoints of a greater

Read the full 408 word article

User Sign In